García Mansilla María José, Rodríguez Sojo María Jesús, Lista Andrea Roxana, Ayala Mosqueda Ciskey Vanessa, Ruiz Malagón Antonio Jesús, Gálvez Julio, Rodríguez Nogales Alba, Rodríguez Sánchez María José
Department of Pharmacology, Centro de investigación Biomédica (CIBM), University of Granada, 18071 Granada, Spain.
Instituto de Investigación Biosanitaria de Granada (ibs.GRANADA), 18012 Granada, Spain.
Nutrients. 2024 Dec 31;17(1):155. doi: 10.3390/nu17010155.
Irritable bowel syndrome is a common functional gastrointestinal disorder characterized by recurrent abdominal discomfort, bloating, cramping, flatulence, and changes in bowel movements. The pathophysiology of IBS involves a complex interaction between motor, sensory, microbiological, immunological, and psychological factors. Diversity, stability, and metabolic activity of the gut microbiota are frequently altered in IBS, thus leading to a situation of gut dysbiosis. Therefore, the use of probiotics and probiotic-derived metabolites may be helpful in balancing the gut microbiota and alleviating irritable bowel syndrome symptoms. This review aimed to report and consolidate recent progress in understanding the role of gut dysbiosis in the pathophysiology of IBS, as well as the current studies that have focused on the use of probiotics and their metabolites, providing a foundation for their potential beneficial effects as a complementary and alternative therapeutic strategy for this condition due to the current absence of effective and safe treatments.
肠易激综合征是一种常见的功能性胃肠疾病，其特征为反复出现的腹部不适、腹胀、绞痛、肠胃胀气以及排便习惯改变。肠易激综合征的病理生理学涉及运动、感觉、微生物、免疫和心理因素之间的复杂相互作用。肠易激综合征患者的肠道微生物群的多样性、稳定性和代谢活性经常发生改变，从而导致肠道生态失调。因此，使用益生菌和益生菌衍生代谢物可能有助于平衡肠道微生物群并缓解肠易激综合征症状。本综述旨在报告和整合在理解肠道生态失调在肠易激综合征病理生理学中的作用方面的最新进展，以及目前专注于益生菌及其代谢物使用的研究，鉴于目前缺乏有效且安全的治疗方法，为它们作为这种疾病的补充和替代治疗策略的潜在有益效果提供依据。
